- There's a lot going on in that area, and I wanted to mention some early data from Caribou Biosciences, a gene-editing company founded by CRISPR pioneer Jennifer Doudna and colleagues.
- Caribou has been working on a therapy for B-cell non-Hodgkin's lymphoma (B-NHL), targeting patients who have gone through several therapies already and are now in need of something new.
- They've reported treatment of five B-NHL patients so far, all of whom had gone through anywhere from two to eight prior therapies and had relapsed to their present uncontrolled state.
For further details see:
Crispred CAR-T Cells In The Clinic